Written and maintained by CASRAI Editorial Board
Published
This page describes products and general use; it is not medical advice.
On this page
Short Answer
Kaltostat is a sterile primary wound dressing made of 80% calcium alginate and 20% sodium alginate from brown seaweed (Laminaria hyperborea). Contact with exudate triggers sodium-calcium ion exchange, converting fibers into a cohesive moist gel while releasing calcium ions that promote local capillary hemostasis in moderate to heavily exuding wounds.
Definition and Scope
Kaltostat is a primary wound dressing for moderately to heavily exuding acute and chronic wounds. Developed by Calgon Vestal Laboratories and produced by ConvaTec Inc., Kaltostat is an alginate biopolymer dressing. Unlike pure sodium alginates that dissolve, Kaltostat pairs calcium and sodium salts to create an intact fleece that swells into a cohesive gel pad or packing ribbon.
Kaltostat is cleared under US Food and Drug Administration (FDA) 510(k) clearances K892364 (dressing), K892868 (packing), and K921009 (Fortex), listed under product codes FRO, QSY, and KMF (21 CFR 880.5090, Class I), verifiable via the openFDA medical device dataset. The dressing is gamma-sterilized, single-use, and latex-free.
Clinical indications include Stage II to IV pressure injuries, venous and arterial ulcers, diabetic foot ulcers, donor sites, second-degree burns, incisions healing by secondary intention, and post-debridement capillary oozing.
How It Works or How It Is Used in Practice
Kaltostat relies on polymer chemistry and ion exchange. Alginic acid consists of β-D-mannuronate (M-blocks) and α-L-guluronate (G-blocks). Harvested from Laminaria hyperborea, Kaltostat is rich in guluronic acid. Calcium ions crosslink adjacent G-blocks into an ‘egg-box’ coordination network, providing mechanical strength.
On exuding wounds, sodium ions (Na+) displace calcium ions (Ca2+) in the fibers. Binding sodium, fibers absorb up to fifteen times their dry weight, forming a hydrophilic gel. The G-block backbone preserves structural crosslinks, yielding high wet tensile strength that permits clean, one-piece removal without leaving debris.
Concurrently, released calcium ions act as Coagulation Factor IV at the wound bed, stimulating platelets and accelerating the clotting cascade to control capillary oozing across bleeding margins.
Clinical handling guidelines include:
- Wound Cleansing: Irrigate using sterile saline or hypochlorous acid wound cleansers like Puracyn; pat periwound skin dry.
- Dry Placement: Apply dry directly to the wound base. Cut or fold the sheet to fit margins, avoiding overlapping intact skin to prevent maceration.
- Cavity Packing: Place rope loosely into tunnels without pressure, leaving at least 2.5 cm (1 inch) outside for retrieval.
- Secondary Dressing: Cover with an absorbent secondary dressing, such as a bordered silicone foam wound dressing or gauze.
- Wear Time: Wear time reaches up to 7 days, governed by exudate volume. Moisten with saline prior to removal if the gel appears dry.
Types or Related Concepts
Formularies differentiate alginates from alternatives based on polymer structure, wet tensile strength, and clotting activity. The table below compares Kaltostat with primary dressing classes.
| Dressing Category & Example | Polymer Composition | Hydrated Gel Structure | Fluid Absorption | Hemostatic Action | CMS HCPCS Code |
|---|---|---|---|---|---|
| Calcium-Sodium Alginate (Kaltostat) |
80% Calcium / 20% Sodium Alginate (G-block rich) | Cohesive fiber-gel sheet; high wet tensile strength | High (15× dry weight); vertical wicking | Active: Ca2+ release accelerates Factor IV clotting | A6196 (≤16 sq in), A6197 (16–48 sq in), A6199 (rope) |
| Pure Calcium Alginate (Sorbsan / Algisite M) |
100% Calcium Alginate (M-block rich) | Soft amorphous gel; dissolves partially on wound | High; conforms to irregular contours | Active: Calcium displacement promotes clotting | A6196 (≤16 sq in), A6197 (16–48 sq in), A6199 (rope) |
| Hydrofiber (Aquacel) |
100% Sodium Carboxymethylcellulose | Cohesive micro-gel sheet; locks fluid inside fibers | Very high; locks fluid vertically | Passive: Physical tamponade only (no ion release) | A6196 (≤16 sq in), A6197 (16–48 sq in), A6199 (rope) |
| Polyurethane Foam (Allevyn / Biatain) |
Hydrophilic polyurethane open-cell foam | Retains sponge structure; expands with exudate | Moderate to high; fluid retention plus MVTR | None: Physical compression only | A6209 (≤16 sq in), A6210 (16–48 sq in) |
| Antimicrobial Barrier (Silverlon) |
Pure metallic silver on nylon matrix | Non-gelling, flexible knitted fabric | Low; functions as non-adherent contact layer | None: Antimicrobial barrier reduction | A6206 (≤16 sq in), A6207 (16–48 sq in) |
Where It Matters for Labs, Clinics, or Supply Decisions
Formulary selection balances clinical efficacy against acquisition cost and reimbursement rules. In US outpatient wound care, coding adheres to Healthcare Common Procedure Coding System (HCPCS) Level II codes under the Centers for Medicare & Medicaid Services (CMS) Durable Medical Equipment (DME) benefit.
CMS DME MAC Policy Article A54563 defines reimbursement categories for alginate dressings:
- HCPCS A6196: Alginate dressing, wound cover, sterile, pad size ≤16 sq. in., each (e.g., Kaltostat 5 cm × 5 cm or 7.5 cm × 12 cm).
- HCPCS A6197: Alginate dressing, wound cover, sterile, pad size >16 but ≤48 sq. in., each (e.g., Kaltostat 10 cm × 20 cm).
- HCPCS A6198: Alginate dressing, wound cover, sterile, pad size >48 sq. in., each (e.g., Kaltostat 30 cm × 60 cm).
- HCPCS A6199: Alginate dressing, wound filler, sterile, per 6 inches (e.g., Kaltostat 2 g rope).
Medicare coverage requires documented moderate-to-heavy drainage. Dressings are approved for daily changes during acute drainage, tapering to two or three changes weekly as exudate decreases. Rope billing under A6199 requires recording the length inserted in 6-inch units.
In biomedical research, Kaltostat provides a reference biomaterial for wound repair assays. Investigators use standardized swatches in animal models to evaluate re-epithelialization and vascular endothelial growth factor (VEGF) expression under controlled moisture.
Supply officers should note Kaltostat’s 5-year shelf life after gamma irradiation and room temperature storage (15°C to 30°C / 59°F to 86°F). Wear time up to 7 days reduces secondary dressing waste and nursing labor costs.
Common Misunderstandings
- Use on Dry Wounds: Kaltostat requires exudate to activate gelling. Applying it to dry eschar causes fibers to adhere to tissue, generating pain and trauma during removal.
- Assuming Complete Internal Resorption: Although alginate fibers biodegrade, Kaltostat is not an internal surgical implant. Leaving rope in closed cavities risks foreign-body reaction; all material must be retrieved.
- Treating Arterial Hemorrhage: Kaltostat controls capillary oozing via Factor IV calcium release, but cannot replace surgical ligation or compression for high-pressure arterial bleeding.
- Fearing Systemic Hypercalcemia: Local calcium exchange is confined to the superficial exudate interface. Pharmacodynamic data confirm that released calcium does not alter serum calcium levels.
- Use in Third-Degree Burns: Full-thickness third-degree burns lack the vascularity and exudate required for alginates; these injuries require surgical excision and grafting.
Frequently Asked Questions
What is the difference between Kaltostat and Aquacel?
Kaltostat is a calcium-sodium alginate dressing that releases calcium ions to support capillary clotting while forming a gel sheet. Aquacel is made of 100% sodium carboxymethylcellulose (Hydrofiber), which locks fluid vertically without releasing calcium ions.
Can Kaltostat dressings be cut to fit a wound?
Yes. Kaltostat pads can be trimmed dry with sterile scissors to match wound margins. The fleece maintains structural integrity without fraying.
How long can Kaltostat remain on a wound?
Kaltostat can remain in place for up to 7 days. Changes should occur earlier if exudate strikes through the secondary cover dressing.
Does Kaltostat require a secondary cover dressing?
Yes. Kaltostat is a non-adhesive primary contact layer. It requires a secondary dressing, such as a silicone foam or composite dressing, to secure it and retain moisture.
Is Kaltostat indicated for infected wounds?
Kaltostat may be used on clinically infected wounds under clinician supervision, provided appropriate antimicrobial therapy is administered concurrently.
Sources
- ConvaTec Inc. “Kaltostat Calcium Sodium Alginate Dressing Instructions for Use.” Product Labeling & Technical Documentation. Accessed November 10, 2026. https://www.convatec.com/wound-care/dressings/alginate-dressings/kaltostat/
- US Food and Drug Administration. “510(k) Premarket Notification K892364: Kaltostat Wound Dressing.” CDRH. Cleared June 23, 1989. Accessed November 10, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K892364
- US Food and Drug Administration. “510(k) Premarket Notification K921009: Kaltostat Fortex Wound Dressing.” CDRH. Cleared May 29, 1992. Accessed November 10, 2026. https://api.fda.gov/device/510k.json?search=k_number:K921009
- Centers for Medicare & Medicaid Services. “Local Coverage Article A54563: Surgical Dressings – Policy Article.” Medicare Coverage Database. Accessed November 10, 2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=54563
- Williams, C. “Kaltostat.” British Journal of Nursing 3, no. 19 (1994): 1001-1002. PMID: 7994152. Accessed November 10, 2026.
- Lansdown, A. B., et al. “An evaluation of the local reaction and biodegradation of calcium sodium alginate (Kaltostat) following subcutaneous implantation in the rat.” J R Coll Surg Edinb 39, no. 5 (1994): 284-288. PMID: 7861335. Accessed November 10, 2026.
- Sintler, M. P., et al. “Randomized trial comparing Quixil surgical sealant with Kaltostat hemostatic dressing to control suture line bleeding after carotid endarterectomy.” World J Surg 29, no. 10 (2005): 1300-1304. PMID: 16136287. Accessed November 10, 2026.







